Application of thymic factor "Thymalin" in complex treatment of endometrial cancer patients.
Bakhidze. E V EV
Key Findings
- Thymalin was added to standard hormone therapy and surgery in 35 endometrial cancer patients
- Patients receiving thymalin showed modest improvements in immune cell counts
- Some clinico‑morphological (tissue) parameters improved with thymalin
Practical Outcomes
- The results suggest thymalin might help the immune system during cancer treatment, but there’s no clear guidance for using it to boost longevity, metabolism, or performance in healthy people. Biohackers should view this as early, disease‑specific data rather than a ready‑to‑use protocol.
Summary
A study gave the peptide thymalin to 35 women with endometrial cancer who were also getting hormone therapy and surgery. The researchers saw some improvement in immune cell numbers and a few tissue‑level changes, but the work was limited to cancer patients and didn’t show how thymalin could be used for general health or performance.
Abstract
Indications have been received of cell immunity in 111 primary endometrial cancer patients in the process of complex treatment: hormonotherapy+surgery. These indices have revealed correlation with pathogenetic variants of disease. Suppression has also been registered of T-lymphocytes under the influence of complex treatment. 35 patients received thymic factor "Thymalin" as a component of complex treatment. Its positive effects on cell immunity and some clinico-morphological parameters have been registered.
Study Information
pubmed
1990